Altered Dynein Axonemal Assembly Factor 1 Expression in C-Boutons in Bulbar and Spinal Cord Motor-Neurons in Sporadic Amyotrophic Lateral Sclerosis

Pol Andrés-Benito, Mr, Mónica Povedano, MD, Pascual Torres, Mr, Manuel Portero-Otín, PhD, and Isidro Ferrer, MD, PhD

Abstract
Dyneins are major components of microtubules. Dynein assembly is modulated by a heterogeneous group of dynein axonemal assembly factors (DNAAFs). The present study analyzes dynein axonemal assembly factor 1 (DNAAF1) and leucine-rich repeat-containing protein 50 (LRRC50), the corresponding encoded protein, in lower motor neurons in spinal cord of sALS postmortem samples and hSOD1-G93A transgenic mice at the age of 90 days (preclinical stages), and the number of motor neurons with LRRC50-immunoreactive structures is also significantly decreased in hSOD1-G93A transgenic mice at the age of 90 days (preclinical stages), and the number of motor neurons with LRRC50-immunoreactive structures is significantly reduced in animals aged 150 days (clinical stages). These observations suggest cholinergic degeneration of motor neurons as a pathogenic factor in motor neuron disease. LRRC50 protein levels were not detected in human CSF.

Key Words: Amyotrophic lateral sclerosis, Biomarkers, Dynein axonemal assembly factor 1, LRRC50, Motor-neurons, Spinal cord.

INTRODUCTION
Neuronal microtubules are intracellular structures that facilitate a myriad of neuronal functions, including activity-dependent axonal transport (1), which is governed by the dynein/kinesin system (2, 3). Anterograde transport, mediated by kinesins, supplies distal axons with newly synthesized proteins and lipids, including synaptic components required to maintain presynaptic activity, whereas retrograde transport, mediated by dyneins, is required to maintain homeostasis by removing aging proteins and organelles from the distal axon for degradation and recycling of components (1, 3).

Dynein is a dimer composed of the motor-containing heavy chain and the distal tail formed by intermediate chains, light intermediate chains, and light chains. The motor domain is in the C-terminus and is responsible for microtubule binding, inasmuch as the N-terminal tail domain is responsible for dimerization, dynein interaction with other proteins (e.g. dynactin), and cargo interaction (3–6).

Amyotrophic lateral sclerosis (ALS) is a multifactorial disease characterized by the degeneration of motor neurons, their axons, and neuromuscular synapses (7, 8). Microtubule alterations, including abnormal kinesin/dynein and related interactors, are critical factors in the pathogenesis of this disease (9–18). In addition, Golgi complex disruption results from abnormal dynein/dynactin interactions (6). Since recent transcriptomics observations have identified significant reduction in the expression of a cluster involving several axonemal dynein transport components in the anterior horn of the spinal cord (SC) in sporadic ALS (sALS) (19), the ensuing study analyzes dynein axonemal assembly factor 1 (DNAAF1) and leucine-rich repeat-containing protein 50 (LRRC50), the corresponding encoded protein, in lower motor neurons in sALS compared with controls. LRRC50 is a dynein up-stream effector that participates in the cytoplasmic preassembly of dynein arms and is involved in the regulation of microtubule-based cilia and actin-based brush border microvilli. Different mutations in LRRC50 result in distinct clinical syndromes,
including abnormal assembly of cilia in respiratory epithelia producing primary ciliary dyskinesia, altered cardiac laterality, and polycystic kidney (20–22). The distribution and localization of LRRC50 in the nervous system is not known. The present study has identified LRRC50 in C-boutons of motor neurons of the SC and selected motor nuclei of the brain stem in sALS, and decreased LRRC50 immunoreactivity in sALS and in SOD1 transgenic mice as a model of unrelated motor neuron disease.

**MATERIALS AND METHODS**

**Human Tissue Samples**

Paraffin-embedded postmortem fresh-frozen and 4% formalin-fixed samples of the lumbar SC and medulla oblongata were obtained from the Institute of Neuropathology HUB-ICO-IDIBELL Biobank following the guidelines of the Spanish legislation (Real Decreto de Biobancos 1716/2011) and the approval of the local ethics committee of the Bellvitge University Hospital-Institute of Biomedical Research IDIBELL. The postmortem interval between death and tissue processing was from 2 to 17 hours. Transversal sections of the SC were alternatively frozen at −80°C or fixed by immersion in 4% buffered formalin. Age-matched control cases had not suffered from neurologic or psychiatric diseases and did not have neuropathologic lesions. Genetic testing, using genomic DNA isolated from blood or brain tissue, revealed no mutations in the chromosome 9 open reading frame (C9orf72), superoxide dismutase 1 (SOD1), TAR DNA binding protein (TARDBP), or FUS RNA binding protein (FUS). Cases in the present series used for biochemical studies (i.e. quantitative reverse transcription PCR [RT-qPCR]) are summarized in the Table. Cases used for immunohistochemical studies did not correspond always with those of the biochemical series; this group was composed of 16 sALS 10 age-matched controls as described in the corresponding section. Variable numbers of TDP-43-P-immunoreactive neuronal and oligodendroglial inclusions and neurite threads were found in the anterior horn of the SC in every ALS case. Neuronal inclusions were small, round intracytoplasmic deposits, large globular inclusions and skein-like inclusions. Neuronal inclusions were present in only ~20% of the remaining motor neurons in ALS.

**Animal Model hSOD1-G93A**

Transgenic mice expressing high copy numbers of the mutated form of human SOD1 (hSOD1), B6SJL-Tg(SOD1* G93A)1Gur/j (hSOD1-G93A) were obtained from The Jackson Laboratories (Bar Harbor, ME). The colony was maintained using breeding male hemizygous carriers with nontransgenic B6SJL females. Offspring were identified by PCR, and non-transgenic G93A littermates were used as wildtype controls. In addition, unrelated WT mice were examined. Animals were maintained under standard animal housing conditions (static isolation caging, 3–4 animals per cage) in a 12-hour dark-light cycle with free access to food and water. The first series of immunohistochemical studies was performed on 5 hSOD1-G93A mice, 3 control littermates, and 3 WT aged 150 days. The second series of histochemical studies was carried out on the SCs of 5 animals per stage: 90 days (preclinical), 120 (early clinical), and 150 (late clinical). Genotyped mice were dissected for immunohistochemical studies. All the procedures were carried out after the approval of the Animal Ethics Committee of the University of LLeida.

**RNA Extraction and RT-qPCR**

RNA from dissected human frozen anterior horn of the lumbar SC of 14 sALS (mean age 61 years; 6 men and 8 women) and 13 age-matched controls (mean age 59 years; 8 men and 5 women) was extracted following the instructions of the supplier (RNeasy Mini Kit, Qiagen, Hilden, Germany). RNA integrity and 28S/18S ratios were determined with the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA) to assess RNA quality, and the RNA concentration was evaluated using a Nanodrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Complementary DNA (cDNA) preparation used the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) following the protocol provided by the supplier. Parallel reactions for each RNA sample were run in the absence of MultiScribe Reverse

**TABLE. Summary of Cases Used for Biochemical Study**

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>Diagnosis</th>
<th>PM Delay</th>
<th>Initial Symptoms</th>
<th>RIN Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>59</td>
<td>M</td>
<td>Control</td>
<td>12 h 05 min</td>
<td>–</td>
<td>6.4</td>
</tr>
<tr>
<td>2</td>
<td>43</td>
<td>M</td>
<td>Control</td>
<td>05 h 55 min</td>
<td>–</td>
<td>6.6</td>
</tr>
<tr>
<td>3</td>
<td>47</td>
<td>M</td>
<td>sALS</td>
<td>04 h 55 min</td>
<td>–</td>
<td>5.6</td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>F</td>
<td>Control</td>
<td>11 h 20 min</td>
<td>–</td>
<td>6.2</td>
</tr>
<tr>
<td>5</td>
<td>46</td>
<td>M</td>
<td>Control</td>
<td>15 h 00 min</td>
<td>–</td>
<td>5.9</td>
</tr>
<tr>
<td>6</td>
<td>56</td>
<td>M</td>
<td>Control</td>
<td>07 h 10 min</td>
<td>–</td>
<td>6.1</td>
</tr>
<tr>
<td>7</td>
<td>71</td>
<td>F</td>
<td>Control</td>
<td>08 h 30 min</td>
<td>–</td>
<td>5.9</td>
</tr>
<tr>
<td>8</td>
<td>64</td>
<td>F</td>
<td>Control</td>
<td>05 h 00 min</td>
<td>–</td>
<td>7.0</td>
</tr>
<tr>
<td>9</td>
<td>79</td>
<td>F</td>
<td>Control</td>
<td>06 h 25 min</td>
<td>–</td>
<td>6.7</td>
</tr>
<tr>
<td>10</td>
<td>75</td>
<td>M</td>
<td>Control</td>
<td>07 h 30 min</td>
<td>–</td>
<td>5.0</td>
</tr>
<tr>
<td>11</td>
<td>55</td>
<td>M</td>
<td>Control</td>
<td>09 h 45 min</td>
<td>–</td>
<td>5.3</td>
</tr>
<tr>
<td>12</td>
<td>76</td>
<td>M</td>
<td>Control</td>
<td>06 h 30 min</td>
<td>–</td>
<td>6.6</td>
</tr>
<tr>
<td>13</td>
<td>51</td>
<td>F</td>
<td>Control</td>
<td>04 h 00 min</td>
<td>–</td>
<td>6.3</td>
</tr>
<tr>
<td>14</td>
<td>56</td>
<td>M</td>
<td>sALS</td>
<td>10 h 30 min</td>
<td>N/A</td>
<td>7.1</td>
</tr>
<tr>
<td>15</td>
<td>70</td>
<td>M</td>
<td>sALS</td>
<td>03 h 00 min</td>
<td>Respiratory</td>
<td>7.3</td>
</tr>
<tr>
<td>16</td>
<td>77</td>
<td>M</td>
<td>sALS</td>
<td>04 h 30 min</td>
<td>N/A</td>
<td>7.4</td>
</tr>
<tr>
<td>17</td>
<td>56</td>
<td>F</td>
<td>sALS</td>
<td>03 h 45 min</td>
<td>N/A</td>
<td>8.2</td>
</tr>
<tr>
<td>18</td>
<td>59</td>
<td>M</td>
<td>sALS</td>
<td>03 h 15 min</td>
<td>N/A</td>
<td>7.5</td>
</tr>
<tr>
<td>19</td>
<td>63</td>
<td>F</td>
<td>sALS</td>
<td>13 h 30 min</td>
<td>Bulbar</td>
<td>6.8</td>
</tr>
<tr>
<td>20</td>
<td>59</td>
<td>F</td>
<td>sALS</td>
<td>14 h 15 min</td>
<td>N/A</td>
<td>6.4</td>
</tr>
<tr>
<td>21</td>
<td>64</td>
<td>M</td>
<td>sALS</td>
<td>16 h 30 min</td>
<td>N/A</td>
<td>6.3</td>
</tr>
<tr>
<td>22</td>
<td>57</td>
<td>F</td>
<td>sALS</td>
<td>04 h 00 min</td>
<td>Bulbar</td>
<td>6.2</td>
</tr>
<tr>
<td>23</td>
<td>75</td>
<td>F</td>
<td>sALS</td>
<td>04 h 05 min</td>
<td>Bulbar</td>
<td>6.8</td>
</tr>
<tr>
<td>24</td>
<td>79</td>
<td>F</td>
<td>sALS</td>
<td>02 h 10 min</td>
<td>N/A</td>
<td>7.0</td>
</tr>
<tr>
<td>25</td>
<td>57</td>
<td>F</td>
<td>sALS</td>
<td>10 h 00 min</td>
<td>Bulbar</td>
<td>6.5</td>
</tr>
<tr>
<td>26</td>
<td>46</td>
<td>M</td>
<td>sALS</td>
<td>07 h 00 min</td>
<td>Spinal</td>
<td>7.0</td>
</tr>
<tr>
<td>27</td>
<td>69</td>
<td>F</td>
<td>sALS</td>
<td>17 h 00 min</td>
<td>Spinal</td>
<td>6.4</td>
</tr>
</tbody>
</table>

Abbreviations: sALS, sporadic amyotrophic lateral sclerosis cases; M, male; F, female; PM, postmortem delay (hours, minutes); N/A, not available; RIN, RNA integrity number.
Transcriptase to assess the lack of contamination of genomic DNA. TaqMan RT-qPCR assays for DNAAF1 (Hs00698399_m1) were performed as detailed elsewhere (19). Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) was used as internal control for normalization of SC samples. The double-delta cycle threshold (ΔΔCT) method was utilized to determine the fold change values. The obtained data were analyzed with the t-test.

Immunohistochemistry

Dewaxed 4-μm-thick sections of the SC and medulla oblongata in human cases and SC in mice were processed for immunohistochemistry. The human series included 16 sALS (mean age 57 years; 6 men and 8 women) and 10 age-matched controls (mean age 62 years; 6 men and 4 women). Immunohistochemistry in murine SCs was performed in 5 × 3 transgenic mice (5 animals at the ages of 90, 120, and 150 days) and 3 × 2 controls (3 control littermates and 3 WT aged 150 days). The sections were boiled in citrate buffer (20 minutes) to retrieve protein antigenicity. Endogenous peroxidases were blocked by incubation in 10% H2O2 solution (15 minutes) followed by 3% normal horse serum solution. Then the sections were incubated at 4°C overnight with one of the primary antibodies: LRRC50 (1/200, polyclonal rabbit, Abcam, Cambridge, UK); vesicular acetylcholine transporter: VAcHT (1/100, polyclonal guinea pig, Synaptic Systems, Goettingen, Germany); and sigma 1 receptor: S1R (1/100, monoclonal mouse, Santa Cruz Biotechnology, Santa Cruz, CA). Following incubation with the primary antibody, the sections were incubated with EnVision ÷ system peroxidase (Dako, Agilent Technologies) for 30 minutes at room temperature. The peroxidase reaction was visualized with diaminobenzidine and H2O2. Control of the immunostaining included omission of the primary antibody; no signal was obtained following incubation with only the secondary antibodies. No positive controls were used.

Double-Labeling Immunofluorescence and Confocal Microscopy

Dewaxed 4-μm-thick sections of human and mouse control SCs were stained with a saturated solution of Sudan black B (Merck, Glostrup, Denmark) for 15 minutes to block the autofluorescence of lipofuscin granules present in cell bodies, and then rinsed in 70% ethanol and washed in distilled water. The sections of human cases were incubated at 4°C overnight with double combinations (double-labeling) of LRRC50 (1/200, polyclonal rabbit, Abcam, Cambridge, UK) and VAcHT (1/100, polyclonal guinea pig, Synaptic Systems) or S1R (1/100, monoclonal mouse, Santa Cruz Biotechnology) or synaptophysin (monoclonal mouse antibody used at 1/500, Leica Biosystems, Wetzlar, Germany) or TDP43-P Ser409/Se410 (1:200, MABN14 rat, Millipore, Burlington, MA). Other sections were triple labeled with LRRC50, VAcHT, and S1R. The sections of mice were processed for double-labeling immunofluorescence with antiLRRC50 and antiS1R antibodies. After washing, the sections were incubated with the respective fluorescence secondary antibodies Alexa555, Alexa488, and/or Alexa657 (1:400, Molecular Probes, Eugene, OR) against the corresponding host species. Nuclei were stained with DRAQ5 (dilution 1:2000, BioStatus, Loughborough, UK). After washing, the sections were mounted in Immunofluore mounting medium (ICN Biomedicals, Irvine, CA), sealed, and dried overnight. Sections were examined with a Leica TCS-SL confocal microscope. Control of the immunostaining included omission of the primary antibody; no signal was obtained following incubation with only the secondary antibodies.

Quantification and Statistical Analysis

Quantification of LRRC50 expression in human histological sections was made directly from the ocular of the microscope at a magnification of ×200 by counting the number of motor-neurons containing LRRC50-positive boutons in (i) the whole anterior horn of the lumbar SC, (ii) motor nucleus of the vagus nerve, and (iii) hypoglossal nucleus (HN) in 3 different sections separated 100 μm for every region in every sALS and control case. A similar approach was used to quantify motor-neurons with VAChT- and S1R-positive structures. Quantitative studies in mice were carried out only in the ventral horn of the SC following the same protocol. Quantification was made by one person blinded to the clinical status. The normality of distribution of counted cell number was analyzed with the Kolmogorov-Smirnov test. The unpaired t-test was performed to compare each group when values followed a normal distribution. Statistical analysis and graphic design were performed with GraphPad Prism version 5.01 (La Jolla, CA). Results were analyzed with the Student t-test. Outliers were detected using the GraphPad software QuickCalcs (p < 0.05). The data were expressed as mean ± SEM and significance levels were set at *p < 0.05, **p < 0.01, and ***p < 0.001.

ELISA in CSF

Samples were obtained from sALS patients and controls as detailed elsewhere (23). CSF (1.5 ± 0.5 mL) was collected in polypropylene tubes as part of the clinical routine investigation. CSF was centrifuged at 3000 rpm for 15 minutes at room temperature. Supernatant was collected and aliquoted in volumes of 250 μL and stored at –80°C until use. All samples were analyzed after one freeze/thaw cycle. Quantification of LRRC50 was performed using the Human Dynein assembly factor 1, axonalin, LRRC50 ELISA Kit (Catalogue No MBS9317767, MyBioSource, San Diego, CA) following the manufacturer’s instructions.

RESULTS

In agreement with a previous study (19), DNAAF1 mRNA expression levels in the anterior horn of the SC were significantly reduced in sALS compared with controls (p = 0.019; Fig. 1A).

LRRC-50 immunoreactivity in the human control SC and brainstem was restricted to immunoreactive boutons in motor neurons, and walls in the blood vessels. Such boutons were elongated, oval-shaped, 1–5 μm in length, and mainly localized at the periphery of the cytoplasm near the plasma...
membrane of the cell body and proximal dendrites (Fig. 1B, C). The number of LRRC50-immunoreactive boutons per neuron was as high as twenty-five in a single paraffin section. However, the number of LRRC50-immunoreactive boutons was markedly reduced in the remaining motor neurons in the anterior horn of the SC in sALS cases ($p = 1.10 \times 10^{-18}$; Fig. 1D–F). Similar LRRC50-immunoreactiveboutons were found in contact with the cytoplasm and proximal dendrites of motor neurons in the dorsal motor nucleus of the vagus nerve and the HN in control cases, but their number was smaller in comparison with anterior horn motor neurons. A similar reduction in the number of LRRC50-immunoreactive boutons was found in the remaining motor neurons in the dorsal motor nucleus of the vagus nerve ($p = 1.2 \times 10^{-7}$) and in the HN ($p = 4.3 \times 10^{-8}$) in sALS (Fig. 1G–I). Curiously, LRRC50 in several motor neurons in sALS had a perinuclear distribution instead of its presence in boutons (Fig. 1I).

In contrast to the motor nuclei of the hypoglossal nuclei and vagus nerves, LRRC50-positive boutons were absent in the oculomotor nuclei of the brainstem in normal (control) brains (data not shown).

LRRC50 structures were similar in morphology to C-boutons on motor neurons of the spinal horn, as revealed by vesicular acetylcholine transporter (VACHT) and sigma 1 receptor (S1R) immunohistochemistry (Fig. 2). Moreover, VACHT- and S1R-positive motor neuron boutons were largely decreased in sALS cases ($p = 8.75 \times 10^{-6}$ and $p = 1.15 \times 10^{-12}$, respectively; Fig. 2E, H).

**FIGURE 1.** DNAAF1 and LRRC50 expression in human control and sALS lower motor neurons. (A) Reduced DNAAF1 mRNA expression in the anterior horn of the lumbar spinal cord in sALS compared with age-matched controls. (B, C) LRRC50 immunoreactivity in anterior horn motor neurons in controls identifies oval-shaped structures (boutons) at the periphery of the cytoplasm and proximal dendrites. (D) The percentage of motor neurons with LRRC50-immunoreactive dots is significantly decreased in the anterior horn of the spinal cord (SC) in sALS when compared with controls. (E, F) This decrease is due to the almost total absence of LRRC50-positive boutons in the remaining sALS motor neurons. (G) Similar reduction is found in the hypoglossal nucleus (HN) and motor nucleus of the vagus nerve (DNV) in sALS when compared with controls. (H, I) Representative images of the motor nucleus of the vagus nerve in control and sALS showing marked reduction, almost absence of LRRC50-immunoreactive boutons. Note perinuclear LRRC50 immunoreactivity in some motor neurons in sALS (arrows) but not in controls. LRRC50 immunoreactivity is also present in capillaries (ca). Paraffin sections slightly counterstained with hematoxylin; scale bar = 25 μm. Unpaired t-test, *$p < 0.05$, ***$p < 0.001$. 
Double- and triple-labeling immunofluorescence to LRRC50 and S1R, VAChT, and synaptophysin in controls showed that LRRC50-immunoreactive boutons colocalized or were in close contact with VAChT or with S1R and synaptophysin-immunoreactive C-boutons (Fig. 3), thus supporting the idea that LRRC50 was a component of C-boutons. Double-labeling immunofluorescence and confocal microscopy to LRRC50 and TDP-43-P showed that loss of C-boutons was found equally in neurons with and without TDP-43-P-immunoreactive inclusions. This was not unexpected as TDP-43-P inclusions were observed in a minority of remaining motor neurons in ALS whereas loss of LRRC50 boutons was generalized in the anterior horn of the SC in ALS (data not shown).

Motor neurons of the SC in control mice (SOD1 littermates and WT mice) showed similar oval or round LRRC50-immunoreactive structures in the cytoplasm (Fig. 4). LRRC50-positive structures were in close proximity or colocalized with S1R as revealed by double-labeling immunofluorescence and confocal microscopy (Fig. 4). No differences were seen between control littermates and WT mice at the age of 150 days. However, LRRC50 positivity was significantly decreased in motor neurons in hSOD1-G93A transgenic mice aged 150 days (p = 0.001; Fig. 4).

To learn whether loss of LRRC50 immunoreactivity was an early or a late event in the progression of motor neuron degeneration, hSOD1-G93A transgenic mice at preclinical and early clinical stages, 90 and 120 days old, respectively, were examined. As shown in Figure 5, the number of positive structures per neuron was decreased at the age of 90 days (preclinical stage) in hSOD1-G93A transgenic mice compared with controls (p = 0.03). The reduction was still noted at the age of 120 days although it was not significant (p = 0.14).

Finally, to test whether LRRC50 in the CSF might serve as a complementary biomarker in sALS, LRRC50 levels were measured using a commercial quantitative sandwich ELISA kit. The detection range was from 3.12 ng/mL to 100 ng/mL. Levels of LRRC50 were not detectable in the CSF of controls and sALS cases.
DISCUSSION

Dynein processing and localization varies in different cell types and clusters in distinct subcellular organelles (24–27). In the central nervous system, dyneins are largely localized at the axon terminals (27). Dynein assembly is modulated by a heterogeneous group of DNAAFs that act, in most instances, in combination with particular chaperones to promote cytoplasmic pre-assembly of dyneins (28–33). Mutations in certain DNAAFs such as NADYX1C1, ZYYND10, C11orf70 (encoding CFAP300: cilia and flagella associated protein 300), and PIH1D3 result in abnormal dynein assembly (30, 34–40). Likewise, mutations in DNAAF1 result in abnormal assembly of cilia in respiratory epithelia, infertility, altered cardiac laterality, and polycystic kidney (20–22).

The present study identifies the presence of LRRC50-immunoreactive boutons at the surface of motor neurons of the
SC and motor nuclei of the brain stem in humans and mice, which are identified as C-boutons on the basis of single immunohistochemistry, and double- and triple-labeling immunofluorescence and confocal microscopy. C-boutons are pre-synaptic terminals of cholinergic interneurons localized in the SC and in most of the motor nuclei of the cranial nerves excepting the oculomotor nuclei of the brainstem (41–47). They contain VACHT and synaptic vesicle markers, and are in contact with postsynaptic components including M2 muscarinic receptors and S1R; neuregulin 1-ErB retrograded signaling is also differentially compartmentalized in C-type boutons (43, 46–49). Cholinergic interneurons modulate motor neuron activity through C-boutons (43–45, 50). On the basis of the present findings, LRRC50 may be considered a component of C-boutons involved in dynein assembly and retrograde axonal transport.

In agreement with our previous gene transcription observations, DNAAF1 mRNA expression is reduced in the SC anterior horn in sALS cases. Reduced DNAAF1 mRNA expression can be the result of mere motor neuron demise. However, LRRC50 immunoreactivity is drastically reduced at the surface of the remaining spinal and bulbar motor neurons, in parallel with reduced numbers of C-boutons, in sALS.

FIGURE 4. LRRC50-immunoreactive boutons in motor neurons of the spinal cord in mice. (A, B) LRRC-50 immunoreactivity is found in cytoplasmic structures in control mice. (C) Double-labeling immunofluorescence and confocal microscopy depicts close proximity and partial colocalization of LRRC50 (green) and S1R (red) immunoreactivity. (D) LRRC50 immunoreactivity is almost depleted in motor neurons in hSOD1-G93A transgenic mice aged 150 days (clinical stage). (E) Quantification of motor-neurons with LRRC50-positive structures is significantly reduced in transgenic mice when compared with wild type littermates. Unpaired t-test: ***p < 0.001. Paraffin sections; scale bars: A, B, D, bar = 25 μm; C = 15 μm.
FIGURE 5. LRRC50 (red) and S1R (green) immunoreactivity in motor-neurons of the ventral horn of the spinal cord in control and hSOD1-G93A transgenic mice aged 90 (A, B) and 120 (C, D) days. LRRC50 and S1R immunoreactivity is decreased in transgenic animals when compared with controls (A–D), although some LRRC50- and S1R-positive structures are still present in neurons in transgenic mice. Asterisks indicate the localization of the cytoplasm of motor neurons. (E) Quantitative studies show a significant decrease in the number of LRRC50- and S1R-immunoreactive structures in transgenic mice aged 90 days (preclinical stage) and a trend at the age of 120 days when compared with control littermates. Unpaired t-test: *p < 0.05. Paraffin sections; scale bar = 25 μm.
Therefore, LRRC50 reduction is not the mere reflection of motor neuron demise but a reduction in the number of LRRC50-immunoreactive boutons in the remaining motor neurons in sALS.

This decline occurs independently of the aberrant formation of TDP-43-immunoreactive inclusions in certain motor neurons in classical sALS (7, 8). This decline neither correlates with the appearance of dynein-dynactin-immunoreactive deposits in motor neurons, which are also not related with skein-like inclusions, in the SC in sALS (51). However, LRRC50 reduction in C-boutons is accompanied by perinuclear LRRC50 immunoreactivity in some remaining motor neurons thus suggesting some kind of alteration in the transport of this protein.

Loss of cholinergic synapses in the SC motor-neurons in sALS was reported many years ago (52). That pioneering observation was not studied further in humans but was partially refuted in SOD1 transgenic mice (53, 54). This is due in part to the different markers used to detect C-boutons in SOD1 transgenic mice. A significant increase in the number of NRG1-positive boutons was observed at the beginning of the symptomatic stage which was followed by a marked decrease at end stages of the disease. A similar pattern occurred for VACHt boutons, but some motor-neurons depleted of VACHt-immunoreactive boutons showed high numbers of NRG1-positive dots (46). Our present observations show a marked reduction in LRRC50-immunoreactive boutons in motor neurons of the ventral horn in hSOD1-G93A transgenic mice aged 150 days which is accompanied by a parallel decrease in, but not the absence of, S1R-immunoreactive boutons. The presence of the remaining S1R seems to be protective of motor neurons, as the knocking-out of S1R in hSOD1-G93A transgenic mice exacerbates motor neuron disease progression in these animals (55). Early pre-symptomatic alterations in C-boutons has been reported in SOD1(G93A)tg mice (56). Interestingly, viral-mediated delivery of type III-NRG1 to the SC restores the number of C-boutons and extends the survival time of SOD1-ALS mice (57).

Our combined study in human sALS not linked to SOD1 mutations and in transgenic mice bearing high copy numbers of the mutated form of human SOD1 show common responses regarding C-boutons in motor neurons. The number of LRRC50-immunoreactive structures is decreased in motor neurons in both paradigms. To learn whether observed alterations in ALS are early or late events, transgenic mice at preclinical, early clinical and late clinical stages were examined. A decrease in LRRC50 immunoreactivity occurs at preclinical stages in hSOD1-G93A transgenic mice, suggesting that LRRC50 alteration is an early event in the course of the disease. A trend to decrease is observed at the age of 120; lack of significance can be due to the relative low number of animals examined or to a transient attempt to compensation. However, a significant decrease is manifested at the age of 150 days.

The pattern of C-bouton response in sALS and Tg mice differs from that seen after nerve peripheral nerve axotomy in mice. Reduced expression of VAChT and NRG1 differences from that seen after nerve peripheral nerve axotomy. Reduced expression of VAChT and NRG1 differs from that seen after nerve peripheral nerve axotomy. Reduced expression of VAChT and NRG1 differs from that seen after nerve peripheral nerve axotomy.

ACKNOWLEDGMENTS

We wish to thank B. Torrejón Escrivano for technical help with the confocal microscopy and T. Yohannan for editorial assistance.

REFERENCES


Downloaded from https://academic.oup.com/jnen/advance-article-abstract/doi/10.1093/jnen/lzn539/5426209 by Bukkyo University Library user on 03 April 2019